Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

Launched by INSTITUT CLAUDIUS REGAUD · May 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a specific type of blood cells called double-positive circulating cells, which may help doctors better understand certain metastatic cancers—cancers that have spread from their original site. The trial includes patients with nine types of cancer, such as kidney cancer, prostate cancer, and melanoma, among others. If you or a loved one has been diagnosed with one of these cancers and has not yet started treatment, you might be eligible to participate. Participants must be at least 18 years old and covered by French Social Security.

During the study, which only lasts for one day, you will provide a blood sample before starting any anti-cancer treatment. This sample will be analyzed using different methods to look for the specific cells being studied. Overall, the trial aims to gather information that could be helpful for future cancer treatments. It’s important to know that this trial is not yet recruiting participants, so if you're interested, you may need to wait until it begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with one of the following cancer types: urothelial carcinoma, renal carcinoma, prostate adenocarcinoma, upper aerodigestive tract carcinoma, cervival carcinoma, adenocarcinoma of endometrium, cutaneous melanoma, soft tissue sarcoma, seminomatous and nonseminomatous germ cell tumors
• • 2. Metastatic disease for which the treatment (whatever the line) has not been initiated yet
• • 3. Age ≥ 18 years
• • 4. Patient affiliated to a French Social Security scheme
• • 5. Patient having signed his/her informed consent prior to inclusion in the study and prior to any specific procedure for the study.
• Exclusion Criteria:
• • 1. Patient with localized disease.
• • 2. Pregnant or breast-feeding women.
• • 3. Any psychological, family, geographical or sociological condition that prevents compliance with the medical monitoring and/or procedures set out in the study protocol.
• • 4. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).